Navigation Links
New Data Support Use of Simple Test to Predict Endometrial Cancer Response to Chemotherapy
Date:6/1/2009

Study Presented at 2009 American Society of Clinical Oncologist Annual Meeting

ORLANDO, Fla., June 1 /PRNewswire/ -- New data presented today at the 2009 American Society of Clinical Oncologist (ASCO) Annual Meeting support the use of a laboratory test, ChemoFX(R), to help physicians predetermine the effectiveness of chemotherapy in treating a woman's endometrial cancer. Investigators found a significant correlation between the test results from 405 patient specimens analyzed using ChemoFx and published patient response rates for each chemotherapeutic regimen, suggesting less effective therapies could be eliminated prior to patient administration. Endometrial cancer is the most common gynecologic cancer among women in the United States.

"Limiting a patient's exposure to chemotherapy is important, however determining the appropriate treatment the first time for a woman with endometrial cancer can be challenging," said Dr. Warner K. Huh, MD., Lead Investigator and Associate Professor, Division of Gynecologic Oncology, University of Alabama at Birmingham, "These data suggest a more targeted approach could be achieved by testing the effect of various chemotherapeutic agents on a woman's tumor before a therapy is administered to the patient, potentially bypassing use of ineffective therapies."

Published data suggest that individual patients will only respond to a single chemotherapy agent 30 percent of the time and while combination therapy can increase a patient's response up to 60 percent, finding the combination that will achieve that response can prove difficult. The unintended consequences of ineffective treatment include, but are not limited to, patient exposure to the toxic aspects of the chemotherapy and delay in the patient receiving potentially beneficial treatments. ChemoFx is a test that quantifies an individual cancer patient's probable tumor response to various chemotherapeutic
'/>"/>

SOURCE Precision Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care
2. Global Creative, Media and Technology Agency LBi Launches Cutting Edge Social Movement for the British Red Cross in Support of Refugee Week
3. Prairie Island Indian Community Supports Fight Against Diabetes Locally and Nationally
4. Concurrent Technologies Corporation Awarded Contract to Support the Centers for Disease Control and Prevention with Readiness Efforts
5. New Virginia Poll: 71 Percent of Voters Strongly Support FDA Regulation of Tobacco Products
6. New Mississippi Poll: Voters Strongly Support FDA Regulation of Tobacco Products
7. Craneware Supports Hospitals Compliance and Upfront Collections with Accurate Estimates
8. Spanish-Speaking OmniPod Customer Support Now Available Around-the-Clock
9. Voters Urged to Support Budding Moves to Include Long Term Care in National Health Reform
10. Kindred Healthcare Supports the Flag and the Sacrifices it Represents
11. Childrens Health Fund Receives $500,000 from the Starr International Foundation to Support South Bronx Homeless Health Care Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 Degenerative changes to the area of ... with compression, known as the nucleus pulposus, has been demonstrated ... new study led by researchers at the Icahn School of ... journal PLOS ONE, reinforces the importance of diabetes in inducing ... is the first study to demonstrate that these changes can ...
(Date:5/17/2013)... A May 13, 2013 report by CNN ... Getting Surgery” examines the typical motivation of post-divorce ... to the article these patients typically fit into three ... freshen their look because they’re now back on the ... plastic surgery before their divorce but never went ...
(Date:5/17/2013)... New York (PRWEB) May 17, 2013 ... dedicated to protecting the rights of victims injured by ... DePuy Orthopaedics Inc. has said in a May 16, ... some of its metal-on-metal and ceramic-on-metal hip replacement products; ... and the Complete Ceramic-on-Metal Acetabular Hip System will no ...
(Date:5/17/2013)... women in Texas who are found to have an ... one of their breasts end up having an old-fashioned ... is malignant. Since 2001, national expert panels have recommended ... breast lumps or masses should be minimally invasive biopsy. ... ultrasonographic or X-ray guidance, with either a fine needle ...
(Date:5/17/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) -- There ... a musical instrument and a GPS system, and now there,s ... you,re having a heart attack. The app, which was ... diagnose certain kinds of severe heart attacks, called STEMIs, before ... in the experimental stage, but it has undergone field testing. ...
Breaking Medicine News(10 mins):Health News:Degenerative Changes Identified in Spinal Discs and Reversed With Drug Cocktail In Diabetic Mice 2Health News:Degenerative Changes Identified in Spinal Discs and Reversed With Drug Cocktail In Diabetic Mice 3Health News:Degenerative Changes Identified in Spinal Discs and Reversed With Drug Cocktail In Diabetic Mice 4Health News:Plastic Surgery – Is ‘Revenge’ Cosmetic Surgery on the Rise? 2Health News:Parker Waichman LLP Responds to Johnson & Johnson’s Decision to Discontinue Some of Its DePuy All-metal and Ceramic-on-metal Hip Implant Products 2Health News:Parker Waichman LLP Responds to Johnson & Johnson’s Decision to Discontinue Some of Its DePuy All-metal and Ceramic-on-metal Hip Implant Products 3Health News:More than one-third of Texas women still receive unnecessary breast biopsy surgery 2Health News:Heart Attack? Doctors Soon May Have an App for That 2Health News:Heart Attack? Doctors Soon May Have an App for That 3
... Wellness Festival with ... at 10 a.m., BOSTON, May 31 Cyndi Lauper, in ... from her rehearsal,on Friday night to meet with some of this ... http://www.newscom.com/cgi-bin/prnh/20080531/CLSA004 ), The 23rd Annual AIDS Walk Boston ...
... SAN CLEMENTE, Calif., May 30 Hero Nutritionals,introduced Slice ... adults, at,the Natural Products Expo West in March 2008. ... Coenzyme Q10. Though CoQ10 is found in every cell ... from the word,ubiquitous for ,found everywhere, low levels of ...
... World Report has ranked,Cincinnati Children,s Hospital Medical Center the ... pediatrics in the 2008 edition of,its annual "America,s Best ... has ever received from U.S. News., "This is ... debt of thanks,to the thousands of employees who helped ...
... 30 The National Alliance on,Mental Illness (NAMI) ... to public education about mental illness at NAMI,s ... NAMI executive director Mike Fitzpatrick made the announcement ... which he discussed the premiere of,two television documentaries ...
... BOSTON, May 30 The following is being issued,by the ... 1,200 physician scientists from 58 countries across the globe, ... When: Wednesday, June 4-Monday, June 9, Where: Boston ... To accelerate science that improves patient care, Wednesday, June ...
... Deadline is Dec. 31, but FDA urges asthma patients ... 30 (HealthDay News) -- Asthma inhalers that contain the ... that harm the ozone layer. And these inhalers won,t ... are urging patients to switch to alternative inhalers now. ...
Cached Medicine News:Health News:Sunday's AIDS Walk Boston at the Esplanade Gets Tribute from Cyndi Lauper at True Colors Concert Tour Launch Rehearsal 2Health News:U.S. News Ranks Cincinnati Children's Among Top Three U.S. Children's Hospitals 2Health News:U.S. News Ranks Cincinnati Children's Among Top Three U.S. Children's Hospitals 3Health News:NAMI Blog: PBS, MTV and Jane Pauley 2Health News:World-Renowned Scientists to Lead Immunology Course 2Health News:World-Renowned Scientists to Lead Immunology Course 3Health News:World-Renowned Scientists to Lead Immunology Course 4Health News:Ozone-Depleting Inhalers Being Phased Out 2Health News:Ozone-Depleting Inhalers Being Phased Out 3
(Date:5/17/2013)... 2013  Sorrento Therapeutics, Inc. (OTCBB: SRNE; or ... Small Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) ... Diseases (NIAID), a division of the National Institutes ... human antibody therapeutics to combat Staphylococcus aureus ... including methicillin-resistant S. aureus (MRSA), was ...
(Date:5/17/2013)... 17, 2013  Sony Biotechnology Inc. ("Sony") today announced the ... and 130um sorting chip.  Sony will also be exhibiting its ... SH800 Cell Sorter, the EC800 flow cytometer, and new SP6800 ... 2013, which will be held at the San ... California , from May 20 - 22.  ...
(Date:5/17/2013)... , May 17, 2013  TechAtlas Group ... for their competitive landscape map for the Chronic ... over 90 international companies with drugs and devices ... CKD and its sequelae. (Logo:  ... , hypertension - renal denervation ...
Breaking Medicine Technology:Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Sony Delivers New Technology for Science to CYTO 2013 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2
... Call to discuss the company,s third quarter financial ... 11:00 a.m. EDT (8:00 a.m. PDT). SUNNYVALE, Calif., ... PCYC ) today announced that it has entered ... leading French independent pharmaceutical company. The alliance will ...
... TLR8 Agonist to Advance for Treatment of AllergySAN DIEGO ... biopharmaceutical company focused on the development of novel Toll-Like ... respiratory and inflammatory diseases, announced today that it has ... selective intranasal TLR8 agonist for the treatment of allergic ...
Cached Medicine Technology:Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier 2Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier 3Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier 4Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier 5VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: